Wang SL, Fang H, Hu C, et al. - Among patients who had received breast-conserving surgery and had T1-2N0-3 invasive breast cancers, and were recruited from 4 Chinese institutions, this inquiry was performed to examine if a 3.5-week schedule of hypofractionated radiotherapy (HFRT) was noninferior to a standard 6-week schedule of conventional fractionated radiotherapy (CFRT) in China. Five-year local recurrence (LR) was assessed as primary endpoint, and to establish noninferiority, a 5% margin of 5-year LR was used. A median follow-up of 73.5 months was performed, which revealed that the 5-year cumulative incidence of LR in the HFRT group and the CFRT group was 1.2% and 2.0%, respectively. Overall, it was inferred that similar low LR and toxicity may be noted with CFRT and HFRT with a tumor-bed boost.